[1] Fan JG.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. Journal of gastroenterology and hepatology.2013;28(S1):11-17.
[2] Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese.Journal of gastroenterology and hepatology.2012;27(10): 1555-1560.
[3] Hu W, Shao X, Guo D,et al.Relationship of Serum Betatrophin with Nonalcoholic Fatty Liver in a Chinese Population.PloS one.2017;12(1):e0170758.
[4] Khaw KB, Choi RH, Kam JH,et al.Interval increase in the prevalence of symptomatic cholelithiasis-associated non-alcoholic fatty liver disease over a ten-year period in an Asian population.Singapore medical journal.2017;58(12):703-707.
[5] Lu FB, Hu ED, Xu LM,et al.The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis.Expert review of gastroenterology & hepatology.2018;12(5):491-502.
[6] Vernon G,Baranova A,Younossi ZM.Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.Alimentary pharmacology&therapeutics.2011;34(3):274-85.
[7] White DL, Kanwal F, El-Serag HB.Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.Clinical gastroenterology and hepatology ;the official clinical practice journal of the American Gastroenterological Association.2012;10(12):1342-1359 e2.
[8] Mittal S, El-Serag HB, Sada YH, et al.Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.2016;14(1):124-131e1.
[9] Castera L, Pinzani M. Non-invasive assessment of liver fibrosis: are we ready? Lancet.2010;375(9724):1419-1420.
[10] Alkhouri N,Feldstein AE.Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? Metabolism: clinical and experimental.2016;65(8):1087-1095.
[11] Wong VW, Adams LA,de Ledinghen V,et al.Noninvasive biomarkers in NAFLD and NASH - current progress and future promise.Nature reviews Gastroenterology&hepatology.2018;15(8):461-478.
[12] Fitzpatrick E, Dhawan A.Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.World journal of gastroenterology. 2014;20(31):10851-10863.
[13] Soininen P,Kangas AJ,Wurtz P,et al.Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics.Circulation Cardiovascular genetics.2015;8(1):192-206.
[14] Tzoulaki I,Ebbels TM,Valdes A, Elliott P, Ioannidis JP. Design and analysis of metabolomics studies in epidemiologic research: a primer on -omic technologies. American journal of epidemiology.2014;180(2):129-139.
[15] Zhao L,Zhang J,Pan L,et al.Protective effect of 7,3',4'-flavon-3-ol (fisetin) on acetaminophen-induced hepatotoxicity in vitro and in vivo.Phytomedicine : international journal of phytotherapy and phytopharmacology.2019;58:152865.
[16] Pirola CJ,Sookoian S.Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity.World journal of gastroenterology.2018;24(15):1601-1615.
[17] Procopet B,Fischer P,Farcau O,et al.Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease.World journal of hepatology.2018;10(3):371-378.
[18] National Workshop on Fatty liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Mdeical Association,et al.Guideline of prevention and treatment for nonalcoholic fatty liver disease:a 2018 update.J Mod Med Health.2018,34(5):644-645.
[19] Fan JG, Farrell GC.Epidemiology of non-alcoholic fatty liver disease in China. Journal of hepatology.2009;50(1):204-210.
[20] Loomba R, Sanyal AJ.The global NAFLD epidemic.Nature reviews Gastroenterology & hepatology.2013;10(11):686-690.
[21] Leite NC,Salles GF,Araujo AL,et al.Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus.Liver Int.2009;29(1):113-119.
[22] Hegazy M,Elsayed NM,Ali HM,et al.Diabetes Mellitus,Nonalcoholic Fatty Liver Disease,and Conjugated Linoleic Acid (Omega 6):What Is the Link?.J Diabetes Res,2019;2019:5267025.
[23] Doycheva I,Patel N,Peterson M,et al.Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes.J.Diabetes Complicat.2013, 27(3):293-300.
[24] Chavez-Tapia NC,Tellez-Avila FI, Barrientos-Gutierrez T,et al.Bariatric surgery for non-alcoholic steatohepatitis in obese patients.The Cochrane database of systematic reviews.2010:1(1):CD007340.
[25] Musso G,Gambino R,Cassader M.Obesity,diabetes,and gut microbiota:the hygiene hypothesis expanded?Diabetes care.2010;33(10):2277-2284.
[26] Pillai AA, Rinella ME.Non-alcoholic fatty liver disease:is bariatric surgery the answer? Clinics in liver disease.2009;13(4):689-710.
[27] Wieckowska A, McCullough AJ,Feldstein AE.Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future.Hepatology.2007;46(2): 582-589.
[28] Clark JM, Brancati FL, Diehl AM.Nonalcoholic fatty liver disease. Gastroenterology.2002;122(6):1649-1657.
[29] Younossi ZM.Non-Alcoholic Fatty Liver Disease—A Global Public Health Perspective.J.Hepatol.2019;70 (3):531-544.
[30] Li J,Zou B,Yeo Y H,et al.Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia,1999–2019:a systematic review and meta-analysis.Lancet Gastroenterol Hepatol.2019;4(5):389-398.
[31] Khammas ASA,Hassan HA,Salih SQM,et al.Prevalence and risk factors of sonographically detected non alcoholic fatty liver disease in a screening centre in Klang Valley, Malaysia: an observational cross-sectional study.Porto Biomed J.2019;4(2):e31.
[32] Li Z,Xue J,Chen P,et al.Prevalence of nonalcoholic fatty liver disease in mainland of China: A meta-analysis of published studies.J Gastroenterol Hepatol.2014;29(1):42-51.
[33] Marjot T,Moolla A,Cobbold JF,et al,Non-alcoholic fatty liver disease in adults: Current concepts in etiology,outcomes and management.Endocr Rev.2019;10(20). DOI:10.1210/endrev/bnz009.
[34] Almobarak AO,Barakat S,Khalifa MH,et al.Nonalcoholic fatty liver disease (NAFLD) in a Sudanese population: What is the prevalence and risk factors?.Arab J. Gastroenterol.2014;15(1):12-15.
[35] Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.Hepatology.2018;67 (1):328-357.
[36] Machado M V,Cortez-Pinto H.Non-alcoholic fatty liver disease: What the clinician needs to know.World Journal of Gastroenterology.2014;20(36):12956-12980.
[37] Nguyen LH,Chao D,Lim JK,et al.Histologic changes in liver tissue from patients with chronic hepatitis B and minimal increases in levels of alanine aminotransferase: a meta-analysis and systematic review.Clin Gastroenterol Hepatol.2014;12(8):1262-1266.
[38] Chen CH,Huang MH,Yang JC,et al.Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan.J Gastroenterol Hepatol.2007;22(9):1482-1489.
[39] Azzalini L,Ferrer E,Ramalho LN,et al.Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats.Hepatology.2010;51 (5):1567-1576.
[40] Chavez-Tapia N C,Lizardi-Cervera J,Perez-Bautista O,et al.Smoking is not associated with nonalcoholic fatty liver disease.World Journal of Gastroenterology.2006;12(32):5196-5200.
[41] Liu Y,Dai M,Bi Y,et al.Active Smoking,Passive Smoking,and Risk of Nonalcoholic Fatty Liver Disease (NAFLD):A Population-Based Study in China.J Epidemiol.2013;23(2):115-121.
[42] Lin C,Rountree C B,Methratta S,et al.Secondhand tobacco exposure is associated with nonalcoholic fatty liver disease in children.Environ Res.2014;132:264-268.
[43] Gunji T,Matsuhashi N,Sato H,et al.Light and Moderate Alcohol Consumption Significantly Reduces the Prevalence of Fatty Liver in the Japanese Male Population. Am J Gastroenterol.2009,104(9):2189-2195.
[44] Lazo M,Hernaez R,Eberhardt M S,et al.Prevalence of Nonalcoholic Fatty Liver Disease in the United States: The Third National Health and Nutrition Examination Survey,1988-1994.Am J Epidemiol.2013;178(1):38-45.
[45] Chang Y,Cho YK,Kim Y,et al.Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease:A Cohort Study. Hepatology.2019;69(1):64-75.
[46] Dunn W,Sanyal AJ,Brunt EM,et al.Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD).J.Hepatol.2012;57(2):384-391.
[47] Hajifathalian K,Torabi Sagvand B and McCullough AJ.Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study.Hepatology.2019;70 (2):511-521.
[48] Malik A,Cheah P L,Hilmi I N,et al.Non-alcoholic fatty liver disease in Malaysia: A demographic, anthropometric, metabolic and histological study.J Dig Dis.2007;8(1):58-64.
[49] Fan X,Liu E Y,Hoffman V P,et al.Triglyceride/High-Density Lipoprotein Cholesterol Ratio:A Surrogate to Predict Insulin Resistance and Low-Density Lipoprotein Cholesterol Particle Size in Nondiabetic Patients With Schizophrenia.J Clin Psy.2010;72(6):806-812.
[50] Alkhouri N, Dixon LJ, Feldstein AE.Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal.Expert review of gastroenterology & hepatology.2009;3(4):445-451.
[51] Cusi K.Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.Gastroenterology.2012; 142(4):711-725 e6.
[52] Gentile CL, Pagliassotti MJ.The role of fatty acids in the development and progression of nonalcoholic fatty liver disease.The Journal of nutritional biochemistry.2008;19(9):567-576.
[53] Xu Y,Han J,Dong J,et al.Metabolomics Characterizes the Effects and Mechanisms of Quercetin in Nonalcoholic Fatty Liver Disease Development. International journal of molecular sciences.2019;20(5):1220-1234.
[54] Li J,Zhao Y, Huang C, et al.Serum metabolomics analysis of the effect of exercise on nonalcoholic fatty liver disease.Endocrine connections.2019;8(4):299-308.
[55] Tu LN,Showalter MR,Cajka T, et al.Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice.Scientific reports.2017;7(1):6120.
[56] Zhu H, Wang Z, Wu Y, et al.Untargeted metabonomics reveals intervention effects of chicory polysaccharide in a rat model of non-alcoholic fatty liver disease. International journal of biological macromolecules.2019;128:363-375.
[57] Zello GA, Pencharz PB, Ball RO.Phenylalanine flux, oxidation, and conversion to tyrosine in humans studied with L-[1-13C]phenylalanine.The American journal of physiology. 1990;259(6 Pt1): E835-43.
[58] Burke PA, Stack JA, Wagner D, et al.L-[1-(13)C] Phenylalanine oxidation as a measure of hepatocyte functional capacity in end-stage liver disease.American journal of surgery.1997;173(4):270-273;discussion 3-4.
[59] Ishii Y, Suzuki S,Kohno T,et al.Patients with severe liver cirrhosis followed up by L-[1-(13)C] phenylalanine breath test.Journal of gastroenterology.2003;38(11): 1086-1090.
[60] Chang Y, Ryu S, Sung E,et al.Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clinical chemistry.2007;53(4):686-692.
[61] Felig P, Marliss E,Cahill GF.Plasma amino acid levels and insulin secretion in obesity. The New England journal of medicine.1969;281(15):811-816.
[62] Moretto M,Kupski C,Mottin CC,et al.Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities.Obesity surgery.2003;13(4):622-624.
[63] Mook-Kanamori DO, de Mutsert R, Rensen PC, et al.Type 2 diabetes is associated with postprandial amino acid measures.Archives of biochemistry and biophysics.2016;589:138-144.
[64] Palmer ND,Stevens RD,Antinozzi PA,et al.Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study.The Journal of clinical endocrinology and metabolism.2015;100(3):E463-468